These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6038569)

  • 1. New challenges and new responsibilities.
    Duncan LC
    J Med Assoc Ga; 1967 Jan; 56(1):17-21. PubMed ID: 6038569
    [No Abstract]   [Full Text] [Related]  

  • 2. The 1941 sulfathiazole disaster and the birth of good manufacturing practices.
    Swann JP
    Pharm Hist; 1999; 41(1):16-25. PubMed ID: 11623769
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacist's view of pharmaceutical ads.
    Peterson KC
    N Engl J Med; 1969 Jun; 280(26):1479. PubMed ID: 5786524
    [No Abstract]   [Full Text] [Related]  

  • 4. Professional responsibilities.
    Jenkins WL
    J Am Vet Med Assoc; 1993 May; 202(10):1742-3. PubMed ID: 8514601
    [No Abstract]   [Full Text] [Related]  

  • 5. Costs of submitting an IND and obtaining an effective NDA for a new oral drug.
    Elvers WB
    Pharmacol Ther Dent; 1971 Feb; 1(2):102-10. PubMed ID: 5293558
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of new drugs: report on a survey to determine whether there is a need for more formal training programs in clinical pharmacology.
    Brahen LS; Levy AM
    J Clin Pharmacol J New Drugs; 1969; 9(6):352-8. PubMed ID: 5260198
    [No Abstract]   [Full Text] [Related]  

  • 7. Address to the Parenteral Drug Association.
    Goddard JL
    Bull Parenter Drug Assoc; 1966; 20(6):183-8. PubMed ID: 5956955
    [No Abstract]   [Full Text] [Related]  

  • 8. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The real world--regulations and ethics.
    Schwartz MK
    J Insur Med; 1992; Suppl A():52-6. PubMed ID: 10148495
    [No Abstract]   [Full Text] [Related]  

  • 11. Doughnuts and ethics.
    Maliekal J
    Am J Hosp Pharm; 1990 Jul; 47(7):1530. PubMed ID: 2368741
    [No Abstract]   [Full Text] [Related]  

  • 12. Is generics the question?
    Thawley WA
    Am Pharm; 1987 May; NS27(5):6. PubMed ID: 3604916
    [No Abstract]   [Full Text] [Related]  

  • 13. Code of fair practices.
    Kampmeier RH
    J Tenn Med Assoc; 1967 Nov; 60(11):1230-1. PubMed ID: 6056071
    [No Abstract]   [Full Text] [Related]  

  • 14. Code of fair practices in the promotion of drug products.
    Md State Med J; 1967 Dec; 16(12):139-40. PubMed ID: 6079133
    [No Abstract]   [Full Text] [Related]  

  • 15. A quality assurance program for pharmaceutical purchases.
    Drake CE; Kabat HF
    J Am Pharm Assoc; 1971 Nov; 11(11):612-5. PubMed ID: 5171626
    [No Abstract]   [Full Text] [Related]  

  • 16. New York's generic drug substitution law.
    Kamen A
    N Y State Dent J; 1980 Nov; 46(9):599-604. PubMed ID: 6935574
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial. Industry support for pharmacy continuing education.
    Zellmer WA
    Am J Hosp Pharm; 1976 Oct; 33(10):1003. PubMed ID: 973627
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA and Panalba: a conflict of commercial, therapeutic goals?
    Mintz M
    Science; 1969 Aug; 165(3896):875-81. PubMed ID: 5819616
    [No Abstract]   [Full Text] [Related]  

  • 19. Peddling drugs to docs.
    Heussner RC
    Minn Med; 1994 Jun; 77(6):24-31. PubMed ID: 8041331
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug development and the FDA's Critical Path Initiative.
    Woosley RL; Cossman J
    Clin Pharmacol Ther; 2007 Jan; 81(1):129-33. PubMed ID: 17186012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.